Skip to main content

Table 3 Effect of liraglutide versus placebo on anthropometric and biochemical variables

From: Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study

 

Treatment effect

Difference

95 % CI

p value

Liraglutide

Placebo

Weight, kg

−4.17 (3.49)

−0.98 (2.62)

−3.18 (4.31)

−4.79 to −1.57

<0.001

Waist, cm

−2.80 (4.11)

−0.57 (2.52)

−2.22 (4.89)

−4.16 to −0.29

0.026

BMI, kg/m2

−1.35 (1.10)

−0.31 (0.85)

−1.04 (1.34)

−1.54 to −0.54

<0.001

Systolic blood pressure, mmHg

−8.10 (17.27)

−3.17 (16.07)

−4.93 (23.68)

−13.78 to 3.91

0.263

Diastolic blood pressure, mmHg

−3.13 (12.11)

−3.83 (8.75)

0.70 (17.06)

−5.67 to 7.07

0.826

HbA1C, %

−0.42 (0.34)

−0.04 (0.43)

−0.37 (0.54)

−0.57 to −0.17

<0.001

LDL-cholesterol, mmol/L

−0.25 (0.72)

−0.17 (0.63)

−0.08 (0.96)

−0.47 to 0.30

0.657

HOMA IR, pmol/L

−1.35 (3.18)

−0.57 (2.41)

−0.78 (3.24)

−2.01 to 0.45

0.336

Fasting plasma insulin, pmol/L

−11.73 (57.54)

−1.69 (43.79)

−10.04 (68.27)

−36.01 to 15.93

0.469

Fasting blood glucose, mmol/L

−0.99 (1.11)

−0.62 (0.96)

−0.36 (1.06)

−0.76 to 0.03

0.125

  1. Data are expressed as the mean (SD)
  2. BMI body mass index, HbA1C glycated hemoglobin, LDL low-density lipoprotein, HOMA IR homeostasis model analysis of insulin resistance